Patent details

LUC00012 Product Name: "olaratumab et ses dérivés pharmaceutiquement acceptables (LARTRUVO)"

Basic Information

Publication number:
LUC00012
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP090751033
Legal Status:
Inactive
Application number:
LUC00012
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/16/1143
Marketing Authorization Type:
Marketing Authorization Date:
11/11/2016
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
05/04/2017
First Marketing Authorization date:
11/11/2016
Grant date:
19/06/2017
Activation date:
Publication date:
06/04/2017
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
19/06/2031
SPC Extension Expiration:
19/06/2031
Rejection date:
Withdrawal date:

Owner

From:
05/04/2017
 
 

Name:
ImClone LLC
Address:
450 East 29th Street, 12th Floor, New York, NY 10016, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
05/04/2017
Address:
PO Box 48, 8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2017/02
Publication date:
22/06/2017
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2017/03
Publication date:
21/07/2017
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
30/06/2026
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
06/04/2017 Publication 1
05/04/2017 General Document 2
05/04/2017 Application Form 4
05/04/2017 General Document 3
05/04/2017 General Document 2
05/04/2017 General Document 2
05/04/2017 General Document 35